Regeneron’s COVID-19 Antibody “Cocktail” Granted Emergency Use Authorization by FDA
Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.
Moderna: COVID-19 Vaccine Candidate 94.5% Effective According to Early Phase III Data
The COVE trial’s independent, NIH-appointed Data Safety Monitoring Board (DSMB) has carried out a first interim analysis showing just five cases of COVID-19 in the mRNA-1273 group, compared with 90 seen in the placebo group.
High Genomic Variation Observed in Pediatric COVID-19 Cases
A study carried out by the Children's Hospital Los Angeles shows a high prevalence of the recent D614G variant and other mutations in children infected with SARS-CoV-2, as well as a high level of the 20C clade in severe cases.
Regeneron’s COVID-19 Antibody “Cocktail” Granted Emergency Use Authorization by FDA
Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.
WHO: Remdesivir Has “Little or No Effect” as Hospital COVID-19 Treatment
The WHO’s Solidarity trial, a 405-hospital, 30-country open-label randomized trial among 11,266 hospital inpatients, also tested hydroxychloroquine, lopinavir (co-administered with ritonavir) and interferon regimens, which also failed to show effectiveness in hospital inpatients.
COVID-19 Mortality Risk Strongly Influenced by 8 “Super-Variants”
The Yale research team discovered the variants through an analytically “enhanced” genome-wide association study of more than 1,700 patients whose data was included in the UK Biobank.
Proteogenomic Approach Could Help Tailor Breast Cancer Treatment
Using a combination of proteomic analyses and DNA and RNA sequencing to profile breast cancer tumors could lead to more effective, tailored treatment, suggests research from the Broad Institute and Baylor College of Medicine.
Antibodies for SARS-CoV-2 Persist for Months After Infection
Both studies point to the IgG class of antibodies as the longest-lasting antibodies detectable in the blood and saliva of patients during this timeframe, suggesting that SARS-CoV-2-specific IgG antibodies may serve as promising targets to detect and evaluate immune responses against the virus.
Synthetic Protein Could Be Effective COVID-19 Treatment
The ability to generate high-affinity Spike protein binders that block viral interaction with ACE2, but which are highly stable, and small—“to maximize the density of inhibitory domains”—could have multiple advantages over antibodies for direct delivery into the respiratory system.
Specific Gut Microbes that Trigger Immune Response to Viral Infections Identified
Low-level interferon signaling that offers antiviral protection in the absence of active infection is present in all humans shortly after birth, but where and how this signaling occurs has remained unclear. The newly reported work offers up an explanation for this phenomenon.
Prime Time for the Microbiome
With some positive results in the clinic, there are other encouraging signs the field is maturing and branching into other therapeutic areas such as oncology.
RNA for Medical Analysis
From Mendelian disorders to COVID-19, academic and industrial scientists use these nucleic acids to help diagnose diseases.
Top Women in Precision Medicine
In our second installment of women making their mark in the field, Clinical OMICs interviews Bonnie Anderson of Veracyte, Tina Hambuch of Invitae, and Cindy Perettie of Foundation Medicine.
Saving Baby Nathan
California Medicaid’s pilot program Project Baby Bear delivers better outcomes at lower cost via rapid whole-genome sequencing of critically ill newborns.
Payer Policies not Sole Reason for Inconsistent Utilization of Genomic Testing
A report from the Personalized Medicine Coalition found significant variability in the use of genomic testing for patients not only from state to state, but also within states.
Latest by Topic
![A liquid biopsy test has detected changes in the BRCA1 or BRCA2 genes associated with ovarian and breast cancer that signal when the disease stops responding to treatment through platinum chemotherapy or poly ADP-ribose polymerase (PARP) inhibitors. [Source: © freshidea/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1322-218x150.jpeg "Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective")
